Mode
Text Size
Log in / Sign up
N/A N=60 Randomized Single-blind Treatment

Trial to Test if Antibiotic Ointments & Cream Will Sting After Application on a Minor Wound After Tape Stripping Injury

Sting

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: Mean Change From Post-Tape Stripping in Subject Assessment of Stinging Sensation Immediately After Investigational Product Application — -0.29; 0.82; -0.55; -0.65 units on a scale — p=0.187

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Saline (Drug); Isopropyl Alcohol (Drug); Pain Relieving Cream (Drug); Antibiotic/Pain Relieving Ointment (Drug); Original Ointment (Drug); Pain Relief Ointment (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change From Post-Tape Stripping in Subject Assessment of Stinging Sensation Immediately After Investigational Product Application
-0.29; 0.82; -0.55; -0.65; -0.47; -0.71 0.187
PRIMARY
Mean Change From Post-Tape Stripping in Subject Assessment of Stinging Sensation One Minute After Investigational Product Application
-0.24; -0.35; -0.67; -0.47; -0.50; -0.68 0.023 sig
SECONDARY
Mean Clinician Rating of Overall Wound Condition on Day 1
2.42; 2.10; 2.22; 2.50; 2.32; 2.15
SECONDARY
Mean Clinician Rating of Overall Wound Condition on Day 8
1.43; 1.35; 1.37; 1.35; 1.47; 1.38

Summary

The purpose of this study is to have subjects report whether or not several antibiotic products sting when they are applied to minor wounds created on the inner arms.

Eligibility Criteria

Inclusion Criteria

  • Males and females, 18-75 years of age, of any race or ethnicity, in generally good health as determined by a medically-qualified individual
  • Provide a signed and dated informed consent form prior to start of any study-related procedures
  • Able to comprehend and follow the requirements of the study;
  • Females of childbearing potential must have a negative urine pregnancy test at the Screening/Baseline visit;
  • Male or non-pregnant, non-lactating females agree to the contraceptive requirements (including female partner's use of a highly effective form of birth control. Females must have used the same birth control for 1 month before Screening and continue to use it through 1 month after administration of study drug)
  • Willing and able to comply with the tape stripping and all study procedures and attend the scheduled visits for the duration of the study

Exclusion Criteria

  • Suspected alcohol or substance abuse (e.g., amphetamines, benzodiazepines, cocaine, marijuana, opiates)
  • Females who are pregnant (positive urine pregnancy test at screening/baseline) or breastfeeding
  • Males with a pregnant partner or a partner who is currently trying to become pregnant
  • Using steroidal medication (topical or systemic) currently and within 30 days before Visit 1
  • Ingestion of systemic anti-histamines or analgesics within the 3 days before Visit 1
  • Known sensitivity or allergies to the investigational products, to first aid preparations or local anesthetics (e.g. gauze products, pramoxine), or to adhesive bandages
  • Known allergies to unscented soap
  • Tendency of forming keloids after wounding
  • Tattoos located on the surface of one or both inner (volar) region of forearms
  • Heavily pigmented subjects who could heal with abnormal darkening at the test sites on the inner forearms
  • Presence of excessive hair on the inner forearms which could interfere with the test procedures
  • Presents with skin disorders on the inner arms (cuts, scratches, scars, etc), which in the opinion of the Investigator or qualified designee, will interfere with the study assessment or will create undue risk for the subject
  • Pre-existing or dormant dermatologic skin conditions (e.g., eczema, seborrheic dermatitis, atopic dermatitis, psoriasis, vitiligo, etc.) that could interfere with the outcome of the study as determined by the Investigator or qualified designee
  • Other medical condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02320695). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search